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Serological assays can detect anti-SARS-CoV-2 antibodies, but their sensitivity often comes at 
the expense of specificity. Here we developed a Tripartite Automated Blood Immunoassay 
(TRABI) to assess the IgG response against SARS-CoV-2. Calibration was performed with 90 60 
prepandemic and 55 virologically and clinically confirmed COVID-19 samples. Posterior probabil-
ities were calculated from 3x8 measurements of logarithmically diluted samples against the ecto-
domain and the receptor-binding domain of the spike protein and the nucleocapsid protein. We 
then performed 948’528 assays on 5’503 prepandemic and 34’019 copandemic samples from 
hospital patients and healthy blood donors. The seroprevalence increased in March 2020 (0.3%; 65 
CI95%: 0.1% - 0.5%) among hospital patients but plateaued in April at 1.1-1.3%, and dropped to 
0.3-0.7% in July. A dynamic transmission model describing SARS-CoV-2 transmission and sero-
conversion in the general population of the Canton of Zurich yielded an infection fatality ratio of 
0.6% (CI95%: 0.4%-0.8%), similarly to other European areas. While the evolution of seropreva-
lence points to a high effectiveness of containment measures, our data highlight that antibody 70 
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Within just a few months of the onset of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pandemic, several million cases and hundreds of thousands of fatalities from coronavirus 
disease 2019 (COVID-19) have been registered. It has also indirectly caused many more deaths 
by hijacking healthcare resources, thereby making them unavailable to patients suffering from 
other diseases. In addition, COVID-19 has created profound economic distress for most travel-80 
related industries. Finally, it has disrupted a plethora of industrial supply chains, resulting in a 
massive worldwide unemployment crisis that will cost many more human lives.  
In order to alleviate the direct consequences of the SARS-CoV-2 pandemic, governments and 
public healthcare agencies need granular and reliable data on the prevalence of infection, the 
incidence of new infections, and the spatial-temporal oscillations of these parameters within re-85 
gions of interest. The acquisition of such data, however, is daunting and data are prone to misin-
terpretation (1). Firstly, data needs to be acquired extremely rapidly. Secondly, their usefulness 
is dependent on being representative of large populations, meaning that they need to be acquired 
in massive numbers. Finally, the tolerance of false-positives and false-negatives must be ex-
tremely low in order to ensure an accurate estimation of the prevalence; the estimation is partic-90 
ularly challenging in low-prevalence areas. 
Intuitively, PCR-based diagnostics would seem suitable to fulfill the above criteria. However, prac-
tical experience has shown that this is not the case. The acquisition of representative diagnostic 
material for PCR has proven challenging, with deep nasal swabs being difficult to perform, un-
comfortable for patients and potentially hazardous for medical personnel. Accordingly, the sensi-95 
tivity of PCR diagnostics is often disappointing, with reported false-negative rates of 25% even 
under the best conditions (2).  
Serological assays, on the other hand, address the adaptive immune responses of the host which 
are fundamental to limiting viral spread within individuals and populations. While they lag behind 
the viral infection, they can serve as both powerful epidemiological tools as well as useful clinical 100 
aids. Firstly, antibodies can be easily retrieved from many biological fluids, notably including ve-
nous and capillary blood. Secondly, antibodies typically persist for several months whereas the 
viral load in the upper respiratory tract frequently wanes within weeks (3). Importantly, immuno-
logical assays can be largely automated, and are thus suitable to mass screening of extremely 
large cohorts.  105 
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Representative testing of entire populations mandates fully automatable assays capable of out-
putting reliable results at extremely high rates and very low cost. Here we describe an assay that 
fulfills these criteria. We have screened 39'522 samples for antibodies against three SARS-CoV-
2-related antigens: the ectodomain of the spike protein (S), its receptor-binding domain (RBD) 110 
and the nucleocapsid protein (NC), using SARS-CoV-2 enzyme-linked immunoassays (ELISA) 
(4-6). Samples included patients entering the University Hospital of Zurich (USZ), Switzerland, 
from December 2019 to the present (defined as “copandemic”; n=24’830), a cohort of patients 
treated at USZ between 2016 and 2018 (“prepandemic”; n=4’407), as well as 1’096 prepandemic 
and 9’102 copandemic samples from blood donors in Zurich. Our test cohorts were completed by 115 
virologically and/or clinically confirmed cases with SARS-CoV-2 infections (31 annotated USZ 
samples and 56 additionally recruited samples for blood donation service). Our results paint a 
detailed picture of the spread of the pandemic within the greater Zurich area from February to 
July 2020, and may be representative of other metropolitan areas that have been weakly affected 
by SARS-CoV-2 despite a highly mobile population served by large international airports. 120 
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TRABI: a miniaturized high-throughput ELISA for multiple SARS-CoV-2 antigens.  
The goal of this project was to assess the rate of seroconversion throughout the course of the 
pandemic in tens of thousands of individuals who may have been exposed to SARS-CoV-2. This 125 
requires high specificity of the assay procedure in order to avoid false-positive results, while not 
compromising its sensitivity and risking to underestimate the prevalence of anti-SARS-CoV-2 an-
tibodies. Equally crucial is the ability to maintain a throughput of >4’000 samples/24h, and to 
minimize the costs of reagents and labor. We achieved these goals (1) by testing for multiple viral 
antigens, (2) by employing extensive automation including contactless fluid-handling, (3) by re-130 
ducing the sample volumes to the nanoliter scale, and (4) by combining multiple antigen meas-
urements via statistical techniques. The TRABI assay described below utilizes contactless acous-
tic dispensing (7, 8) to transfer droplets (2.5 nl each) of plasma into high-density 1536-well plates 
(total volume: 3 µl) and measures the IgG response against viral proteins in an immunosorbent 
format (Fig. 1A and Fig. S1A for detailed procedure). 135 
In order to identify the most suitable viral targets for TRABI, we infected Vero cells with wild-type 
SARS-CoV-2 virus. Cell lysates were then subjected to Western blotting using the plasma of pa-
tients with confirmed COVID-19 (n=7). The bands corresponding to the S and NC proteins were 
prominently visible in infected cells, but were undetectable in non-infected cells and were sup-
pressed by adding soluble S and NC antigen to the patient plasma before incubation with the 140 
Western blot (Fig. 1B). Accordingly, we selected the SARS-CoV-2 spike protein (9), the receptor 
binding domain (RBD, amino acids 330-532 of the S protein), and the nucleocapsid protein (NC, 
amino acids 1-419) as target antigens for TRABI. Each sample was tested at eight consecutive 
two-fold dilution points (1:50 to 1:6400), and the resulting data were fitted to a sigmoidal curve by 
logistic regression. The inflection point (or –log10(EC50)) of each sigmoid was defined as the re-145 
spective antibody titer.  
As reference samples for assay establishment, we utilized a collective of 55 venous plasma sam-
ples drawn at various days post onset of symptoms (dpo) from 27 RT-qPCR confirmed patients 
suffering from COVID-19 and hospitalized at the University Hospital of Zurich (USZ, true posi-
tives), as well as 90 anonymized USZ samples from the prepandemic era (true negatives) (see 150 
Table S1). We then constructed receiver-operating-characteristics (ROC) curves to assess the 
assay quality for each antigen individually. Finally, we created a composite metric that integrates 
S/RBD/NC measurements using quadratic discriminant analysis (QDA). While each single anti-
gen showed excellent discrimination of negatives and positives on samples drawn at ≥14 dpo, the 
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compound models outperformed the individual antigen measurements at 7-13 dpo, where the 155 
emergence of an IgG response is expected to be variable (Fig. 1C, upper panel). We therefore 
used the QDA modeling assumptions to infer the prevalence in large cohorts based on the distri-
butional information of true negatives and true positives (details in Methods) using information 
gained from all three antigens.  
To benchmark TRABI, we compared the results with a high-throughput assay under development 160 
at the University of Oxford as well as assays commercialized by Roche (Elecsys), DiaSorin, Eu-
roImmun, and Abbott (Fig. 1C, lower panel). This comparative assessment was based on 136 of 
146 samples (10 samples were removed from the analysis because of insufficient sample volume 
to perform all tests). While all assays displayed 100% specificity/sensitivity at late time points, 
TRABI scored best at early time points, also when additionally compared to a lateral-flow assay 165 
(Fig. S2A). When these results were plotted as a function of dpo, a temporal pattern emerged 
consistent with the gradual emergence of IgG antibodies within 14 dpo (Fig. 1D).  
Temporal evolution of the SARS-CoV-2 epidemic in the greater area of Zurich 
Due to supply-chain bottlenecks, but also because of the intrinsically narrow window of infectivity, 
testing of individuals for the presence of SARS-CoV-2 nucleic acids has been limited to those at 170 
elevated risk before and after the peak of the epidemic. During that time, individuals with mild 
symptoms were asked to isolate at home, often without being tested for the presence of SARS-
CoV-2 RNA. Thus, the true number of people who underwent an infection with SARS-CoV-2 may 
at best be a rough estimate modelled on data of numbers of hospitalizations and deaths (10). We 
are therefore using TRABI to screen a large sample of Swiss urban populations. To date, we have 175 
screened 39'522 samples from a University Hospital cohort of Zurich (USZ patient cohort) with 
diverse diseases (Table S1) and from the blood donation service (BDS, see Table S1) of Zurich 
(healthy group), starting from December 2019 (Fig. S3A, B).  
To reliably measure the prevalence of seroconversion, we used known positives and negatives 
as internal calibrators for each cohort. These condition-positives/negatives were screened simul-180 
taneously to all other samples using exactly the same procedures. Their annotation as condition 
positives/negatives was performed post-hoc using USZ and BDS databases in the absence of 
serological data. First, we identified all USZ samples with known positive SARS-CoV-2 RT-qPCR 
results (n=175). Condition-positive samples (n=31) were defined as those with (1) clinically man-
ifest COVID-19 pneumonia and (2) positive RT-qPCR for SARS-CoV-2 and (3) venipuncture oc-185 
curring ≥ 14 days after the positive qPCR. To avail of condition-positives from the cohort of blood 
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donors, 56 samples from convalescent individuals with PCR-confirmed SARS-CoV-2 infection 
recruited for a plasmapheresis study were included.  
To determine potentially unspecific results, e.g. due to cross-reactivity with other coronaviruses, 
we screened 5’503 prepandemic samples (condition-negatives). For the BDS cohort, we enriched 190 
the condition-negatives with 2‘100 samples from December 2019 and January 2020 to increase 
the numbers of the assumed negatives and to obtain a more reliable baseline. We tested two 
models: the first model assumes that both the condition-positive and negative data follow distinct 
multivariate Gaussian distribution with unequal covariances (QDA) (Fig. 2A, B), whereas the sec-
ond model is based on Gaussian distributions with equal covariances (LDA) (Fig. S3C, D). LDA 195 
was additionally performed because it allows to verify the distributional assumptions more readily 
(Fig. S3E, F). Using the distributions of the condition negatives and the condition positives, we 
computed the posterior probability (i.e. the probability of an individual to be seropositive as mod-
eled via the distribution of the known condition-negatives and known condition-positives) for all 
data points (see Fig. S3A, B). The respective ROC curves were then plotted (Fig. S3H, I). At 200 
100% specificity, we identified 27/31 of the annotated true positives for the USZ (Fig. S3G) and 
37/56 annotated true positives for the BDS cohort (Fig. S3H). For the BDS cohort, the sensitivity 
increased rapidly with a slight decrease in specificity (at a false-positive-rate of 0.001, we identi-
fied 52/56 condition positives). We then applied this model to estimate the prevalence in the pop-
ulation. No substantial shift above baseline was inferred for samples screened from January and 205 
February (Fig. 2C and Fig. S3I, USZ cohort). A sudden increase in prevalence manifests in March 
(QDA: 0.3% (95% confidence intervals: 0.1%-0.5%) and LDA: 0.3% (CI95%: 0.1%-0.5%)) and 
peaks in April 2020 (QDA: 1.4% (CI95%: 1.0%-1.7%) and LDA: 1.3% (CI95%: 1.0%-1.7%)), in ac-
cordance with the virologically and clinically reported rise in SARS-CoV-2 infections in these 
months. After that, the estimated prevalence started to decline (average value May to beginning 210 
of July 0.9% and 0.8% of QDA and LDA, respectively) with variations on a low level. The BDS 
collective showed a comparable but slightly delayed time course of seroconversion, with the prev-
alence approximating 1.2% in April (QDA: 1.2% (CI95%: 0.7%-1.8%) and LDA: 1.1% (CI95%: 0.6%-
1.7%) and 1.6% in May (QDA: 1.6% (CI95%: 1.0%-2.3%) and LDA: 1.6% (CI95%: 1.0%-2.2%)) (Fig. 
2C and Fig. S3I). After a minimal decrease in June, it drops to 0.7% in early July ((CI95%: 0.3%-215 
1.2%) and LDA: 0.7% (CI95%: 0.27%-1.2%)). 
In order to address the epidemiological implications of these findings, we employed a dynamic 
transmission model that describes infection, hospitalization, recovery, death and seroconversion 
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due to SARS-CoV-2 in the Canton of Zurich (1.5 million). Assuming the BDS samples are repre-
sentative of the general population in the Canton of Zurich, the model accurately describes the 220 
rapid rise in seroprevalence during the second half of March and the month of April (Fig. 2D and 
Fig. S4). Using a maximum likelihood framework, we estimated a seroprevalence of 1.6% (95% 
prediction interval, PI95%: 1.0%-2.2%) by the end of May, and an infection fatality ratio (IFR) of 
0.6% (CI95%: 0.4%-0.8%) for the general population in the Canton of Zurich. 
To challenge the technical reproducibility of TRABI, we selected 210 high-score samples and 122 225 
random samples from known seronegatives and repeated the assays. The screens proved to be 
highly replicable when comparing the duplicates from the same screen (S: R2 = 0.85 among sam-
ples where both could be adequately fitted, see Fig. 2E) and the values from the follow-up screen 
with the values initially derived from serology (for example, 87% among re-screened samples with 
a -logEC50 for S above 2.5 had a -logEC50 value above 2 in the second screen, see Fig. S5). 230 
Antibodies against the RBD of SARS-CoV can bind to the SARS-CoV-2 RBD (11). We therefore 
tested whether samples with high anti-SARS-CoV-2-RBD titers display cross-reactivity with 
SARS-CoV RBD. For visualization, we binned samples into groups of absent, moderate and high 
SARS-CoV-2 RBD titers (–log[EC50] <1.5, 1.5-2, and > 2.5, respectively) and computed their re-
spective QDA-derived posterior probability. For individuals with SARS-CoV-2 RBD titers < 2, a 235 
small fraction showed binding to SARS-CoV RBD at –log(EC50) > 2 (Fig. 2F). However, those 
with strong binding properties to SARS-CoV-2 RBD (> 2.5) clustered at high values for SARS-
CoV RBD, indicating that some anti-SARS-CoV-2 RBD antibodies were cross-reactive to SARS-
CoV RBD. 
In summary, TRABI identified first cases of SARS-CoV-2 seroconversion in April 2020, consistent 240 
with first infections reported in the Zurich area towards the end of February 2020. While data 
obtained from healthy individuals suggest that around 1.5% of blood donors have been infected 
despite the absence of anamnestic COVID-19, the serological prevalence was about 5-fold higher 
than that of RT-qPCR confirmed cases for the same time point. We conclude that at the time of 
writing, seroconversion within the greater area of Zurich is still exceedingly rare and very far from 245 
herd immunity. 
Clinical and demographic characteristics of serologically confirmed SARS-CoV-2 infected hospital 
patients and healthy donors.  
Approximately 22% of the USZ samples stem from repeat venipunctures of patients. For the pur-
pose of the following analyses, these samples were not considered (if multiple draws were avail-250 
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able, the one with the highest posterior probability was used). Seropositivity was defined as hav-
ing a posterior probability > 0.5. USZ cohort had a median age of 55 years (40 – 68) lower and 
upper quartile respectively) with a median for seropositives of 56 years (42 - 65) (Fig. 3A and 
Table S1). BDS cohort for April to July had a median age of 43 years (29 - 54), and seropositives 
had a median age of 32 (26 - 46) (Fig. 3B and Table S1). The majority (88%) of patients in the 255 
USZ cohort stemmed from the Canton of Zurich (including the city of Zurich), with smaller contri-
butions by Cantons Aargau, Schwyz, St. Gallen, and Thurgau (Fig. 3C). Inhabitants of the city of 
Zurich constituted a comparatively larger proportion of SARS-CoV-2 seropositives than the rest 
of the Canton of Zurich.  
The blood of USZ patients was drawn in 39 clinical departments (Fig. 3D), 24 of which treated 260 
patients with a posterior probability > 0.5. In absolute counts, most SARS-CoV-2-positive samples 
were obtained from the Infectious Disease and Hospital Hygiene ward, followed by the depart-
ments of Internal Medicine, Medical Oncology and Hematology, and Cardiology. The wide range 
of medical departments suggests that SARS-CoV-2 seropositive patients do not solely enter the 
hospital for the treatment of COVID-19 but for any condition that requires the attention of a USZ 265 
physician. Seropositivity can be found across all age groups and in both genders (Fig. 3A, B, 
Table S1) and stays relatively stable for a longer time up (up to 100 days) (Fig. 3E), at least in 
hospital patients with known SARS-CoV-2 positive PCR status. Long-term monitoring of SARS-
CoV-2 seropositive individuals will be important to identify comorbidities potentially associated 
with SARS-CoV-2 infections. 270 
Prevalence of anti-SARS-CoV-2 antibodies in prepandemic samples.  
5’503 prepandemic plasma samples (4’407 USZ hospital patients and 1’096 healthy BDS donors) 
were examined for the presence of cross-reactive antibodies against S, RBD and NC of SARS-
CoV-2. Several individuals had a strong antibody response against a single antigen and an ab-
sence of binding to other antigens, reflected in a low posterior probability but high -log(EC50) 275 
value (Fig. S3A, B). We then directly compared prepandemic and copandemic samples in the 
USZ cohort on the basis of single antigens and their respective posterior probabilities. When fo-
cusing on samples with high values for single assays, we observed an enrichment of high poste-
rior probabilities in pandemic but not in the prepandemic group (Fig. 4A). Among samples with 
individual –log(EC50) values above 2 in May and June 2020, 76% (S), 80% (RBD), and 24% (NC) 280 
had a posterior probability > 0.5. In the prepandemic samples, maximally 1 sample with an indi-
vidual assay level above 2 had a posterior probability above 0.5. This enrichment is suggestive 
of a substantial performance improvement when using the combined metric in the USZ cohort.  
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We then compared the immunochemical properties of six prepandemic samples with high binding 
to S, RBD or NC to two samples of confirmed COVID-19 (COVID 1 and 2, see annotation in Fig. 285 
4A). The COVID-19 samples, but not the prepandemic samples, recognized in Western blots the 
S and NC antigens of SARS-CoV-2 expressed by Expi293F (Fig. 4B and Fig. S6A). Additional 
ELISAs performed on the same samples confirmed the initial findings (Fig 4C and Fig. S6B) 
including intact binding to the RBD. The discrepancy between ELISA and Western Blot suggests 
that the RBD is a highly conformational epitope lost upon boiling and SDS denaturation. 290 
To further probe the specificity of the findings, we also carried out competitive ELISAs on pre-
pandemic and COVID patients. First, we determined plasma concentrations close to the EC50. 
Then we pre-incubated appropriately diluted samples with various concentrations of S and RBD 
(0.04-88 and 0.7-1350 nM, respectively). Samples were then transferred onto ELISA plates 
coated with S, RBD, and NC. The concentration-dependent displacement of the measured optical 295 
density was then visualized (Fig. 4D and Fig. S6C). We found that both soluble S and the RBD 
caused a concentration-dependent depletion of the RBD in COVID samples. The S signal could 
not be depleted with RBD, indicating the presence of epitopes other than the RBD. One pre-
pandemic sample (#1, see Fig. S6C) displayed competition of the S signal with soluble S but not 
with soluble RBD. Other prepandemic samples did not show competition at all, suggesting that 300 
their reactivity was due to high concentrations of low-affinity antibodies cross-reacting with SARS-
CoV-2 S. 
Identification of seropositives in healthy donors and clonality of anti-S immune response.  
TRABI enabled the identification of 57 blood donors that underwent regular blood donation at the 
blood donation service of Zurich (Fig. 2B, C) despite clear serological indications of past infection 305 
and antibody titers in the same range as those of PCR-confirmed convalescent individuals (Fig. 
5A). We assessed IgG and IgA antibodies to S, RBD, and NC as well as responses to multiple 
control antigens, in 4 healthy blood donors and 4 convalescent individuals recruited to the BDS. 
We observed binding of IgG antibodies in blood donors and convalescent individuals against S, 
RBD, and NC, with usually lower IgA titers. No binding against the SARS-CoV-2 non-structural-310 
protein 1 (NSP1), or against bovine serum albumin (BSA) was observed.  
To further validate the seropositivity in healthy blood donors, we employed an orthogonal meth-
odology which allows antibody/antigen interactions to be probed in solution, without any immobi-
lization of antigens to a surface. Samples of SARS-CoV-2 convalescent individuals, healthy do-
nors and controls were preincubated with fluorescently conjugated RBD protein. We then moni-315 
tored the increase in the effective molecular weight of an Alexa647-labelled RBD construct in 
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solution upon complex formation with an antibody present in the patient sample. This was 
achieved by measuring the associated decrease in its molecular diffusion coefficient upon binding 
using a microfluidic platform. While no change in diffusion coefficient or the associated hydrody-
namic radius was observed in control samples, all ELISA-positive samples from convalescent and 320 
healthy donors indicated a clear binding of antibodies to RBD (Fig. 5B). We confirmed these 
findings by using the samples of several healthy blood donors and convalescent individuals as 
primary antibodies in Western Blot and detected bands for both S and the NC in the Expi293 cells 
overexpressing the viral proteins but not in the Expi293 control lysate (Fig. 5C).  
To obtain a rough estimate of the clonality and epitope specificity of the immune response raised 325 
against the S protein, we conducted an ELISA-based soluble antigen competition. Competition 
with the RBD lead to a decrease in ELISA signal for RBD but not for S or NC in both convalescent 
individuals and healthy blood donors (Fig. 5D and Fig. S7). Conversely, competition with S de-
creased the signal for both S and the RBD (Fig. 5D), suggesting the presence of antibodies tar-
geting multiple S epitopes, including RBD. Therefore, the immune response against S was poly-330 
clonal and involved multiple viral epitopes.  
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The high-throughput pipeline for SARS-CoV-2 serology described above has enabled us to study 
a cohort of nearly 40’000 samples from the greater area of Zurich over the time span of the pan-335 
demic. In view of the critique levelled at past serological studies (1, 12), we have gone to great 
lengths to assess and validate our technology. For the initial assay calibration, sensitivity was 
measured using a panel of clinically and RT-qPCR-confirmed SARS-CoV-2 sera (n=55) at various 
time points after onset of clinical signs and symptoms and 90 negative controls. A blinded com-
parison with commercial test kits showed that our approach, which combines three individual as-340 
says into one single score, was suitable for large-scale epidemiologic studies.  
A key question of relevance to public health is the proportion of the population that has already 
contracted the virus. As a proxy for the estimation of the underlying infection attack rate in the 
greater area of Zurich, we have used two independent cohorts: (1) unselected patients coming 
from all clinical departments of USZ and (2) healthy individuals donating blood to local blood 345 
banks (BDS). The availability of known positives and negatives in both cohorts allowed us to 
model the posterior probability from the multiple available antigen measurements, using the re-
spective distributions of these intrinsic controls. Combining the metrics did indeed lead to a power 
gain, as shown by the enrichment of samples with high posterior probabilities in excess of the 
single assays during the epidemic. As a possible drawback, the direct modeling of the multivariate 350 
distribution of antigen measurements may hinder the detection of deviations from the modeling 
assumptions. We explored the robustness to modeling assumptions by employing a mixed uni-
variate Gaussian distribution and saw generally good agreement for prevalence estimations. The 
extent of our sampling bolsters our confidence in the representativity and validity of our results.  
In both cohorts, the prevalence of seropositives climbed over the baseline in late March 2020 and 355 
peaked at 1.6% in April, with indications for a slight decrease in prevalence. But are our cohorts 
representative for the population of the greater area of Zurich? On the one hand, the USZ cohort 
consists mostly of individuals suffering from disparate diseases, some of which may be a conse-
quence of SARS-CoV-2 infections. On the other hand, individuals with acute infections are typi-
cally excluded from donating blood. As a consequence, the BDS cohort may be biased against 360 
individuals who may have experienced COVID-19 symptoms and refrained from donating. Yet, 
despite these fundamental differences in their composition, seroprevalence estimates from both 
cohorts are in good agreement. This observation underscores the presumption that the preva-
lence reported here is truly representative of the population under study. Clearly, our study would 
benefit from the inclusion of cohorts with different age architectures, such as e.g. school children 365 
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or individuals staying in retirement homes. While such cohorts have not been introduced in this 
study, the workflow established here could easily be adapted to the investigation of more focal 
populations. 
The low prevalence and the early plateau of SARS-CoV-2 seroconversion in the greater area of 
Zurich is in stark contrast to harder hit metropolitan areas in Switzerland (Geneva) or Spain (Ma-370 
drid) that have reached a seroprevalence above 10% (13, 14). The low prevalence between 1% 
and 2% might be somewhat surprising when considering that Switzerland borders Northern Italy 
whose prevalence of infection was reported to reach 43% in healthcare workers (15), and no 
travel restrictions were imposed between the more severely affected areas of Switzerland (Ticino 
and the Romandie) and Northern Switzerland (16). This illustrates that the implementation of 375 
strong non-pharmaceutical interventions (NPIs) around mid-March (‘lockdown’) successfully pre-
vented further spread of SARS-CoV-2 in Switzerland (10).  
When set in relation to the regional numbers of RT-qPCR-positive cases, our cohort-based esti-
mates of the seroprevalence (1.6% (CI95%: 1.0%-2.2% in May 2020 for BDS) are in line with those 
of more affected regions of Switzerland such as Geneva (seroprevalence: 10.8% (CI95% 8.2–380 
13.9%) beginning of May 2020 (13)) and are about 5-10 times higher than the respective inci-
dence of overt COVID-19 (10, 16). Likewise, the estimated IFR is in excellent agreement to what 
was found in the Canton of Geneva, and for Switzerland overall (17, 18). All these estimates 
reflect a best-case scenario where hospital capacities have never been exceeded and quality of 
care for critically ill patients could always be ensured. 385 
If the seropositive status is long-lasting, the evolution of anti-SARS-CoV-2 seroprevalence should 
reflect the cumulative incidence of new infections with a delay of ≤13 DPO. The data presented 
here are in agreement with hospital surveys suggesting that few transmission events took place 
in Zurich between April (approx. 2 weeks after the enactment of ‘lockdown’ measures) and July. 
The early peak and subsequent decline of seroprevalence in June-July indicates rapid waning of 390 
antibodies directed against SARS-CoV-2 antigens. This decline was robust, occurred in both the 
USZ and BDS cohorts, and is congruent with observations by others (19-21). Assuming that a 
negligible number of infections occurred in June-July, the population-wide half-life of the TRABI 
titer is no longer than 2 months, although individual antibody responses may be a function of 
disease severity (19). If however a significant number of transmissions took place, waning would 395 
be considerably more rapid.  
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This has far-reaching implications for epidemiological assessments. For example, the immunity 
profile of a population several months after the peak of infections might underestimate the under-
lying infection attack rate, thereby skewing inferences on the IFR. Consequently, serosurveys 
repeated over short time windows and extended over multiple months will be necessary to acquire 400 
a realistic picture of the immunity status of a population. 
A recent publication (22) has shown pre-existing anti-SARS-CoV-2 antibodies in unexposed hu-
mans. Our affinity determinations and immunoblots, however, point to fundamental differences 
between prepandemic seropositivity and the immune responses of SARS-CoV-2-infected individ-
uals. While the latter consistently showed high-affinity responses that were clearly visible in West-405 
ern blotting, the few seropositive prepandemic sera were unanimously negative in Western blot-
ting, and equilibrium displacement ELISA of one prepandemic plasma sample suggested a much 
lower affinity despite similar antibody EC50 titers. We conclude that any immune response in un-
infected individuals, whether it represents cross-reactivity with common-cold coronaviruses or 
something else, is of inferior quality and may less likely be protective.  410 
It has been proposed that asymptomatic individuals entail a different, weaker immune response 
to SARS-CoV-2 (23). While follow-up studies including affinity determinations, epitope mapping, 
and in-depth analyses of the B-cell and T-cell receptor repertoires (described in (24-26)) will paint 
a more detailed picture, our data suggests that asymptomatic individuals – identified in the col-
lective of healthy blood donors – entail an antibody response comparable to the one seen in 415 
individuals with clinical signs of SARS-CoV-2. 
Our population-wide screen allows us to address several crucial questions that have been con-
troversially discussed. What is the frequency of truly asymptomatic cases? What is the complete 
spectrum of clinical signs and symptoms with which SARS-CoV-2-infected individuals present? 
Many SARS-CoV-2 patients present with monosymptomatic anosmia caused by olfactory neuritis 420 
(27), and it is conceivable that other illnesses may represent hitherto unrecognized signs of 
SARS-CoV-2 infection. Stratifying the results of our screens by clinical parameters (including in-
ternational classification of diseases (ICD) codes as well as hematological clinical-chemistry val-
ues) will become increasingly important in the years to come, e.g. to protect those at risk, to 
evaluate immune defenses and their possible waning, and to plan vaccination campaigns.  425 
Our study is conceived as a long-term exercise which, given appropriate funding, will be continued 
for the next several years. In addition to allowing precise monitoring of the population, it will also 
enable the determination of titer decays in seropositive individuals as a function of demographic 
indicators and of comorbidities. However, there are societal concerns linked to antibody testing, 
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and scientists must not downplay them. Serology is a powerful medical and epidemiological in-430 
strument, but it can also be misused to stratify the workforce, to discriminate against the non-
immune, and even for far more nefarious deeds. Let's study immune responses, but let's not 
create a dystopian society based on them.   
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Materials and Methods 
Human specimens and data 435 
All experiments and analyses involving samples from human donors were conducted with the 
approval of the local ethics committee (KEK-ZH-Nr. 2015-0561, BASEC-Nr. 2018-01042, and 
BASEC-Nr. 2020-01731), in accordance with the provisions of the Declaration of Helsinki and the 
Good Clinical Practice guidelines of the International Conference on Harmonisation. Specimens 
were denoted according to the following conventions: prepandemic samples: samples collected 440 
before December 2019; COVID samples: samples from patients with clinically and/or virologically 
confirmed SARS-CoV-2 infection; copandemic samples: any samples collected in December 
2019 or thereafter. 
Sample acquisition and biobanking 
Small volumes (< 100 µL) of heparin plasma samples were obtained from the Institute of Clinical 445 
Chemistry at the University Hospital of Zurich as unique bio specimens, biobanked over recent 
years in a high-throughput liquid biobank. We received a maximum of one sample per patient per 
month. After one month, another sample from the same individual would be included if the patient 
visits the hospital and if blood is sent to the Institute of Clinical Chemistry. EDTA plasma from 
healthy donors was obtained from the Blutspendedienst (blood donation service) Kanton Zürich 450 
and Kanton Luzern from donors who signed the consent that their samples can be used for con-
ducting research. 
High-throughput serological screening.  
In order to test the samples for the presence of IgG antibodies directed against SARS-CoV-2 
antigens, high-binding 1536-well plates (Perkin Elmer, SpectraPlate 1536 HB) were coated with 455 
1 µg/mL S or RBD or NC in PBS at 37 °C for 1 h, followed by 3 washes with PBS-T (using Biotek 
El406) and by blocking with 5% milk in PBS-T (using Biotek MultifloFX peristaltic pumps) for 1.5 
h. Three µL plasma, diluted in 57 µL sample buffer (1% milk in PBS-T), were dispensed at various 
volumes (from 1200 nL down to 2.5 nL) into pre-coated 1536-well plates using contactless dis-
pensing with an ECHO 555 Acoustic Dispenser (Labcyte/Beckman Coulter). Sample buffer was 460 
filled up to 3 uL total well volume using a Fritz Gyger AG Certus Flex dispenser. Thereby, dilution 
curves ranging from plasma dilutions 1:50 to 1:6400 were generated (eight dilution points per 
patient plasma sample). After the sample incubation for 2 h at RT, the wells were washed five 
times with wash buffer and the presence of IgGs directed against above-defined SARS-CoV-2 
antigens was detected using an HRP-linked anti-human IgG antibody (Peroxidase AffiniPure Goat 465 
Anti-Human IgG, Fcγ Fragment Specific, Jackson, 109-035-098, at 1:4000 dilution in sample 
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buffer). The incubation of the secondary antibody for one hour at RT was followed by three 
washes with PBS-T, the addition of TMB, an incubation of three minutes at RT, and the addition 
of 0.5 M H2SO4 (both steps with Biotek MultifloFX syringe technology). The final well volume for 
each step was 3 µL. The plates were centrifuged after all dispensing steps, except for the addition 470 
of TMB. The absorbance at 450 nm was measured in a plate reader (Perkin Elmer, EnVision) and 
the inflection points of the sigmoidal binding curves were determined using the custom designed 
fitting algorithm described below. 
Counter screening using commercial and custom-designed platforms 
We used the following commercial tests for the detection of anti-SARS-CoV-2 antibodies in 55 475 
plasma samples of 27 patients who were diagnosed by RT-PCR  to be infected by SARS-CoV-2 
as well as 83-90 plasma samples which were collected before December 2019 and, hence, before 
the start of the COVID-19 pandemics: The double-antigen sandwich electro-chemiluminescence 
immunoassay from Roche diagnostics (Rotkreuz, Switzerland) was performed with the E801 of 
the COBAS8000® system (Roche diagnostics, Rotkreuz, Switzerland). The test detects any an-480 
tibody against the nucleocapsid antigen. The fully automated LIAISON® SARS-CoV-2 chemilu-
minescence immunoassay from DiaSorin (Saluggia, Italy) detects IgG against the S1/S2 antigens. 
The SARS-CoV-2 chemiluminescent microparticle immunoassay from Abbott (Abbott Park, IL, 
USA) detects IgG against the nucleocapsid antigen and was performed on an Architect™ ana-
lyser. Two ELISAs from EUROIMMUN (Lübeck, Germany) detect IgA or IgG against the S1 anti-485 
gen and were performed by the use of a DSX™ Automated ELISA System (DYNEX Technologies 
(Chantilly, VA, USA). The high-throughput serology assay in Oxford (under development) was 
carried out in the Target Discovery Institute, University of Oxford.  High-binding 384-well plates 
(Perkin Elmer, SpectraPlate) were coated with 20 µL of 2.5 µg/mL S o/n at 4°C, followed by 3 
washes with PBS-T and by blocking with 5% milk in PBS-T for 2 h. Blocking buffer was removed 490 
and 20 µL of 1:25 sera diluted in sample buffer (1% milk in PBS-T) was dispensed into S-coated 
wells then incubated for 2 h at RT.  The wells were washed five times with wash buffer and the 
presence of IgGs directed against S was detected using an HRP-linked anti-human IgG antibody 
(Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ Fragment Specific, Jackson, 109-035-098) at 
1:50,000 dilution in 20 µL sample buffer. The incubation of the secondary antibody for one hour 495 
at RT was followed by three washes with PBS-T and the addition of QuantaRed™ Enhanced 
Chemifluorescent HRP Substrate Kit (Thermo Scientific, Waltham Massachusetts, USA) then in-
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cubated for four minutes at RT before the addition of the stop solution. The fluorescence at exci-
tation/emission maxima of ~570/585nm was measured in a fluorescent plate reader (Perkin 
Elmer, EnVision). 500 
Data analysis.  
Data fitting. Data fitting. Eight-dilution points equally spaced on a logarithmic scale are fitted with 
an equation derived from a simple binding equilibrium. The inflection point (-log10EC50) is extracted 
from the fit. Baseline and plateau values are fixed by the respective positive and negative controls 
in a plate-wise fashion and the signal is fitted following these equations: 505 
𝑐𝑐𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = 1 −
1
2
�𝑐𝑐𝑎𝑎𝑐𝑐 + 𝑘𝑘𝑏𝑏 + 1 −�(𝑐𝑐𝑎𝑎𝑐𝑐 + 𝑘𝑘𝑏𝑏)2 + 2(𝑘𝑘𝑏𝑏 − 𝑐𝑐𝑎𝑎𝑐𝑐) + 1�  , 
where cbound , ca and c are concentration of the antigen-antibody, antigen, and blood concentration 
respectively. 
ODsignal = 𝑐𝑐𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 (𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 − 𝑝𝑝𝑏𝑏𝑏𝑏𝑝𝑝𝑏𝑏𝑏𝑏𝑝𝑝) + 𝑝𝑝𝑏𝑏𝑏𝑏𝑝𝑝𝑏𝑏𝑏𝑏𝑝𝑝 
Data preprocessing. All samples that yielded an –log10EC50 of below –3 on any antigen were 510 
labelled as non-fittable and non-detectable. Their dilution curves cannot be differentiated from 
baseline and therefore only an upper bound for the –log10EC50 can be determined. These samples 
were therefore excluded from data fitting but were of course included in ROC analysis and prev-
alence estimation. 
QDA, LDA, and Prevalence estimation. Assume that we have data for 𝑚𝑚 samples with known 515 
serostatus and antibody measurements, that is, we have (𝑋𝑋𝑖𝑖 ,𝑌𝑌𝑖𝑖), 𝑏𝑏 = 1, . . ,𝑚𝑚, where 𝑋𝑋𝑖𝑖 is the vector 
of size 𝑝𝑝 (in our case our antigen measurements) and 𝑌𝑌𝑖𝑖 is a Boolean variable defining group 
membership (in our case, whether the individual is seropositive or not). The QDA model assumes 
multivariate normal distributed 𝑋𝑋𝑖𝑖 given 𝑌𝑌𝑖𝑖: 
 520 
(𝑋𝑋|𝑌𝑌 = 𝑗𝑗)~𝒩𝒩𝑝𝑝�𝜇𝜇𝑗𝑗, Σ𝑗𝑗�. 
 
Further, the model assumes that the prior, that is, distribution of 𝑌𝑌𝑖𝑖  , is known s. t. 𝑃𝑃[𝑌𝑌 = 𝑗𝑗] = 𝜋𝜋𝑗𝑗 
The quadratic discriminant classifier simply assigns each sample to the group which has the larger 
posterior 𝑃𝑃[𝑌𝑌|𝑋𝑋], which is proportional to the joint probability 𝑃𝑃[𝑌𝑌,𝑋𝑋]. 525 
 
Therefore, we assign sample 𝑏𝑏 to group 1 if  
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log (𝑓𝑓𝑥𝑥|𝑦𝑦=1(𝑥𝑥𝑖𝑖)) +  log (𝜋𝜋1) > log (𝑓𝑓𝑥𝑥|𝑦𝑦=0(𝑥𝑥𝑖𝑖)) +  log (𝜋𝜋0), 
 530 
And to group 0 otherwise. To set the prior, one option is to take just the mean of the group sizes. 
However, this is not an ideal option in our case, where we have an additional 𝑏𝑏 samples with 
unknown serostatus to classify: The prevalence in the 𝑚𝑚 samples with known serostatus might 
deviate substantially from the prevalence in population with unknown serostatus. We therefore 
estimate 𝜋𝜋1directly from the data of unknown serostatus using a simple expectation maximization 535 





𝜋𝜋1𝑘𝑘𝑓𝑓𝑥𝑥|𝑦𝑦=1(𝑥𝑥𝑖𝑖) + (1 − 𝜋𝜋1𝑘𝑘)𝑓𝑓𝑥𝑥|𝑦𝑦=0(𝑥𝑥𝑖𝑖)
. 
 540 








After convergence, this yields our estimate of the positive serostatus prevalence in the samples. 545 
Note that the sample ordering according to this classifier is independent of the prior and therefore 
has no impact on an analysis via ROC curves. Further, note that evaluating QDA via ROC anal-
ysis, an out of sample scheme should be employed to avoid biased estimates of performance; we 
chose 10-fold cross-validation throughout. Lastly, note that the strategy does not critically depend 
on the normality assumption but just requires an estimate for the density functions, 𝑓𝑓𝑥𝑥|𝑦𝑦=𝑗𝑗(𝑥𝑥𝑖𝑖). 550 
Even nonparametric estimates could be an option.  
For the LDA approach, we first collapse the antigen measurements per samples according to the 
linear discriminant classifier: 
𝑧𝑧𝑖𝑖 = 𝑥𝑥𝑖𝑖𝑇𝑇Σ0(𝜇𝜇1 − 𝜇𝜇0), 
 555 
Where Σ0 is the covariance estimated from the known negatives only and 𝜇𝜇1, 𝜇𝜇0 are the means 
of the known positives and negatives respectively. The above algorithm is then applied on the 
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resulting one dimensional variable 𝑧𝑧𝑖𝑖. 95% confidence intervals were derived by bootstrap draw-
ing 1000 bootstrap samples, where the number of samples drawn from each annotation group 
(known positives, known negatives and unannotated) was kept constant. 560 
Epidemiological modelling. We adapted a previously described deterministic, population-based 
model for SARS-CoV-2 transmission in Switzerland (28). Using a maximum likelihood framework, 
we fitted the model to aggregated daily numbers of hospitalized and ventilated patients, and 
deaths in the Canton of Zurich from 27 February 2020 to 31 May 2020 (Fig. S3). Data were 
provided by OpenZH, the specialist unit for open government data from the Canton of Zurich (29). 565 
In contrast to the earlier description of the SARS-CoV-2 epidemic in Switzerland overall, we as-
sumed the daily numbers of hospitalized and ventilated patients in the Canton of Zurich to be 
negative binomially distributed. We also included monthly seroprevalence data from BDS for 
model inference assuming the positive samples are binomially distributed. We assumed the rate 
of seroconversion after onset of symptoms to be 1/6 days, i.e., 90% of infected individuals will 570 
have detectable antibodies by day 14 after onset of symptoms. All data and code files are avail-
able on the following GitHub repository: https://github.com/calthaus/swiss-covid-epidemic. 
High-throughput validation screen 
For the validation screen, we picked 60 and 150 samples from BDS and USZ, respectively, that 
had the high average values when summing -logEC50 for both Spike and RBD. Additionally, we 575 
added 52 and 70 randomly selected prepandemic samples for the BDS and the USZ cohort re-
spectively. We supplemented the three antigens used in the first screen (NC, S, RBD of SARS-
SARS-COV-2) with a SARS-CoV RBD antigen. Unlike for the primary screen, we ran all samples 
in duplicates spread over two independent plates. 
Protein production  580 
The proteins were produced and purified at different sites in Zurich (CH), Oxford (UK), Lausanne 
(CH), and Yale University (USA). 
Oxford, SGC. Recombinant proteins were purified as reported previously with small modifications 
(6, 30). Mammalian expression vectors containing secreted, codon-optimized SARS-CoV-2 S 
(pHL-Sec (31); aa. 1-1208, C-terminal 8His-Twin-Strep) and RBD (pOPINTTGNeo; aa. 330-532, 585 
C-terminal 6His) were transiently transfected with linear PEI into Expi239TM cells cultured in roller 
bottles in FreeStyle 293 media. Cell culture media was harvested after 3 days at 37°C for RBD or 
3 days at 30°C for Spike and then buffered to 1X PBS. Proteins were first pulled down on Ni2+ 
IMAC Sepharose® 6 Fast Flow (GE) with stringent washing (>50 CV with 40 mM imidazole). RBD 
was polished on a Superdex 75 16/600 column (GE) equilibrated with 1X PBS, while Spike was 590 
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directly dialyzed into 1X PBS using SnakeSkinTM 3,500 MWCO dialysis tubing. Proteins were 
concentrated with VivaSpin® centrifugal concentrators, centrifuged at 21,000 x g for 30 min to 
remove precipitates, and flash frozen at 1 mg/mL 
Lausanne, EPFL SV PTECH PTPSP and Zurich UZH. The prefusion ectodomain of the SARS-
CoV-2 S protein (the construct was a generous gift from Prof. Jason McLellan, University of 595 
Texas, Austin; see (30)) was transiently transfected either into suspension-adapted ExpiCHO 
cells (Thermo Fisher) or Expi293F (Thermo Fisher) cells with PEI MAX (Polysciences) in 
ProCHO5 medium (Lonza). After transfection, incubation with agitation was performed at 31°C 
and 4.5% CO2 for 5 days.  The clarified supernatant was purified in two steps; via a Strep-Tactin 
XT column (IBA Lifesciences) followed by Superose 6 10/300 GL column (GE Healthcare) and 600 
finally dialyzed into PBS. The average yield was 15 mg/L culture.  
Yale, New Haven. Human codon optimized SARS-CoV (2003) RBD (pEZT containing H7 leader 
sequence; aa. 306-527, C-terminal Avi- and 8His tags) was transiently transfected into Expi293TM 
cells (Thermo Fisher) using the ExpiFectamineTM 293 Transfection kit (Gibco) according to the 
manufacturer’s instructions. Cells were cultured in a 37˚C incubator with 8% humidified CO2 for 4 605 
days after transfection. Culture supernatant was collected by centrifugation (500 x g for 10 
minutes) and RBD was captured using Ni-NTA Superflow resin (Qiagen), washed, and eluted in 
buffer containing 50 mM Tris-HCl pH 8, 350 mM NaCl, and 250 mM imidazole. RBD was further 
purified using an ENrichTM SEC 650 column (Bio-Rad) equilibrated in 1X PBS (Thermo Fisher). 
Peak fractions were pooled and the protein concentration was determined by 280 nm absorbance 610 
with a NanodropTM One Spectrophotometer (Thermo Fisher). Protein was snap frozen in liquid 
nitrogen and shipped on dry ice prior to experiments. 
Zurich, ETH. NSP1 carrying an N-terminal His6-tag followed by a TEV cleavage site was ex-
pressed from a pET24a vector. The plasmid was transformed into E. coli BL21-CodonPlus (DE3)-
RIPL and cells were grown in 2xYT medium at 30 °C. At an OD600 of 0.8, cultures were shifted 615 
to 18 °C and induced with IPTG to a final concentration of 0.5 mM. After 16 h, cells were harvested 
by centrifugation, resuspended in lysis buffer (50 mM HEPES-KOH pH 7.6, 500 mM KCl, 5 mM 
MgCl2, 40 mM imidazole, 10% (w/v) glycerol, 0.5 mM TCEP and protease inhibitors) and lysed 
using a cell disrupter (Constant Systems Ltd). The lysate was cleared by centrifugation for 45 min 
at 48.000 xg and loaded onto a HisTrap FF 5-ml column (GE Healthcare). Eluted proteins were 620 
incubated with TEV protease at 4 °C overnight and the His6-tag, uncleaved NSP1 and the His6-
tagged TEV protease were removed on the HisTrap FF 5-ml column. The sample was further 
purified via size-exclusion chromatography on a HiLoad 16/60 Superdex75 (GE Healthcare), 
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buffer exchanging the sample to the storage buffer (40 mM HEPES-KOH pH 7.6, 200 mM KCl, 
40 mM MgCl2, 10% (w/v) glycerol, 1 mM TCEP). Fractions containing NSP1 were pooled, con-625 
centrated in an Amicon Ultra-15 centrifugal filter (10-kDa MW cut-off), flash-frozen in liquid nitro-
gen, and stored until further use at -80 °C. 
Details of viral proteins used for this study 
For high-throughput serology, the following proteins were used: SARS-CoV-2 S (pHL-Sec; aa. 1-
1208, C-terminal 8His-Twin-Strep) and RBD (pOPINTTGNeo; aa. 330-532, C-terminal 6His) pro-630 
duced at the SGC in Oxford and the nucleocapsid protein from AcroBiosystems (AA Met 1 - Ala 
419, C-terminal his-tag, NUN-C5227). For competitive ELISA, we used: The prefusion ectodo-
main of the SARS-CoV-2 S protein (Lausanne, EPFL SV PTECH PTPSP), the RBD from Tren-
zyme (C-terminal his-tag, P2020-001) and the nucleocapsid protein from AcroBiosystems (AA 
Met 1 - Ala 419, C-terminal his-tag, NUN-C5227). For additional ELISAs following the high-635 
throughput serology, we used: The prefusion ectodomain of the SARS-CoV-2 S protein (Lau-
sanne, EPFL SV PTECH PTPSP), the RBD from Trenzyme (C-terminal his-tag, P2020-001) and, 
nucleocapsid protein from AcroBiosystems (AA Met 1 - Ala 419, C-terminal his-tag, NUN-C5227), 
the SARS-COV-2 NSP1 protein (from Nenad Ban, ETH Zurich), the CMV pp65 protein (Abcam, 
ab43041), and BSA (Thermo Scientific).  640 
Western Blotting 
Expi293F cells were obtained as a gift from Prof. Maurizio Scaltriti (Memorial Sloan Kettering 
Cancer Center, New York). Non transfected control cells and cells overexpressing either His-
tagged S, His-tagged NC or His-tagged RBD domain were lysed in 0,1% Triton X-100/PBS. Total 
protein content in the cellular fraction was quantified using bicinchoninic protein assay (Pierce 645 
BCA Protein Assay Kit, ThermoFisher).  For Western Blotting, 30 µg of ECD-expressing lysate, 
10 µg of NC-expressing lysate and 10 µg of RBD-expressing lysate were loaded all in the same 
well of NU-PAGE 4-12% Bis-Tris gels (ThermoFisher). 50 µg of non-transfected cell lysate were 
loaded as negative control. Gels were run at a constant voltage (150 V) in MES running buffer for 
50 minutes, then transferred onto PVDF membrane with a dry transfer system (iBlot 2 Gel Trans-650 
fer Device, ThermoFisher). The membranes were blocked with 5% SureBlock (Lubio Science) for 
1 hour at room temperature, and then incubated overnight with a 1:100 dilution of patients’ plasma 
in 1% SureBlock, at 4 degrees. The day after, membranes were washed four times with PBS-T 
and incubated for 1 hours with an anti-human secondary antibody, HRP-conjugated, diluted 
1:10000 in 1% SureBlock. The membranes were then washed four times with PBS-T and acquired 655 
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using Immobilon Crescendo HRP Substrate (Merck Millipore) and Fusion SOLO S imaging sys-
tem (Vilber). As a positive control, one membrane was incubated overnight with mouse anti-Histag 
antibody (ThermoFisher, dilution 1:10000 in 1% SureBlock) and subsequently with anti-mouse 
secondary antibody, HRP-conjugated (Jackson, dilution 1:10000 in 1% SureBlock).  
Competitive ELISA 660 
To perform competitive ELISAs, high-binding 384-well plates (Perkin Elmer, SpectraPlate 384 
HB) were coated with 1 ug/mL S or RBD or NC in PBS at 37°C for 1 h, followed by 3 washes with 
PBS-T and by blocking with 5% milk in PBS-T for 1.5 h. Meanwhile, plasma samples were diluted 
to a final concentration close to the EC50, incubated with either RBD (50 ug/mL) or S (12.5 ug/mL) 
and serially diluted (11 dilution points per patient sample, 25 uL per dilution) in a low-binding 384-665 
well plates (Perkin Elmer, high binding SpectraPlate). After 2 h of incubation at RT, 20 uL of all 
the samples were transferred to the previously coated plates and incubated for additional 2 h at 
RT. Then, the plates were washed five times with PBS-T and the presence of IgGs was detected 
using an HRP-linked anti-human IgG antibody (Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ 
Fragment Specific, Jackson, 109-035-098, at 1:4000 dilution in sample buffer). The incubation of 670 
the secondary antibody for one hour at RT was followed by three washes with PBS-T, the addition 
of TMB, an incubation of 5 minutes at RT, and the addition of 0.5 M H2SO4. The absorbance at 
450 nm was measured in a plate reader (Perkin Elmer, EnVision) and the inflection points of the 
sigmoidal binding curves were determined using a custom designed fitting algorithm. 
Microscale diffusional sizing 675 
For the microfluidic binding measurements, 40% of human plasma was added to 10 nM antigen 
and PBS was added to give a constant volume of 20 µL. The antigen used was RBD labelled with 
Alexa Fluor 647 through N-terminal amine coupling. These samples were incubated at room tem-
perature for 40 minutes and the size, hence molecular weight of the formed immunocomplex, was 
determined through measuring the hydrodynamic radius, Rh with microfluidic diffusional sizing 680 
(32) using a Fluidity One W platform (Fluidic Analytics, Cambridge, UK). Following correction of 
fluorescence intensities for serum autofluorescence, the fraction, fd, of RBD to diffuse into the 
distal channel is defined by: 
 
𝑓𝑓𝑏𝑏 =
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Where [AbR] is the concentration of bound RBD, [R]0 is the total concentration of RBD, and ρb  
and ρf are the fractions of bound and free RBD to diffuse into the distal channel, respectively. 
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Fig. 1.  Study overview and establishment of serological pipeline. A. To estimate the preva-835 
lence of SARS-CoV-2 seropositivity in the population, prepandemic and copandemic samples 
from two independent cohorts were analyzed by high-throughput microELISA (TRABI). IgG titers 
against S, RBD and NC were determined and the –log(EC50) was inferred by regression analysis. 
B. Vero cells infected with SARS-CoV-2 (lane 2), but not uninfected cells (lane 1), showed signals 
corresponding to S (black arrow) and NC (blue arrow, pointing at two bands) when immunoblotted 840 
with COVID-19 patient plasma. NC protein undergoes a proteolytic cleavage in SARS-CoV in-
fected VeroE6 cells, resulting in two distinct bands of around 46 and 43 kDa. We confirmed the 
identity of the two bands by probing with an anti-NC antibody (Sino Biologicals, data not shown). 
Spiking of COVID-19 patient plasma with recombinant S and NC led to the disappearance of all 
signals. C. Upper panel: Using 53 samples from confirmed SARS-CoV-2 patients and 83 pre-845 
pandemic samples, we assessed the specificity-sensitivity relationship for all antigens individually 
and after combining all results into a single score (TRABI) using QDA-based posterior probability. 
Between 7 and 13 dpo, approximately 60% of samples were positive (posterior probability >0.5) 
at 100% specificity cutoff, whereas 100% sensitivity was reached at ≥ 14 dpo. Lower panel: 
COVID and prepandemic samples were used to assess the performance of TRABI, commercial 850 
tests (Roche, DiaSorin, Abbott, Euroimmun) and an assay developed at the Target Discovery 
Institute (Oxford). While all tests scored equally at ≥14 dpo, TRABI outperformed all other assays 
at ≤13 dpo. D. Time course of IgG response in 55 samples from 27 COVID patients. IgG antibod-
ies were reliably detectable at ≥13 dpo. Colors represent individual patients. 
 855 
Fig. 2. Evolution of SARS-CoV-2 prevalence in a cohort of Zurich University Hospital (USZ) 
patients and donors from the blood donation service (BDS). A-B. Inflection points of dilution 
curves, denoted -log(EC50), of plasma titrated against S and RBD in the USZ and BDS cohorts. 
Posterior probabilities were calculated using QDA assuming a multivariate Gaussian distribution. 
C. Prevalence of SARS-CoV-2 seropositivity in prepandemic (before December 2019) and co-860 
pandemic samples (from December 2019 to July 2020) estimated using the posterior probabilities 
from the multivariate Gaussian distribution. Bar: 95% confidence intervals (CI). D. Modelled se-
roprevalence fitted to data from BDS. E. TRABI reproducibility was assessed using duplicates run 
in pairs of independent assay plates. F. To assess potential cross-reactivity of SARS-CoV-2 se-
ropositive individuals, we tested 210 high-scoring samples and 122 random samples for binding 865 
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to the RBD of SARS-CoV. SARS-CoV-2 RBD binders with a high posterior probability (same color 
maps as in B) segregated within the higher anti-SARS-CoV-RBD titers. 
 
Fig. 3. Demographic and clinical annotations of the tested cohorts. A. and B. Age and gen-
der pyramids for the USZ (A) and the BDS (B) cohorts with indications of the respective posterior 870 
probability (p > 0.5). A contour of the respective age pyramid for the inhabitants of the Canton of 
Zurich was drawn based on data provided by the statistical service of the Canton of Zurich. The 
narrower age spectrum of blood donors reflects regulatory restrictions of donation. C. Total sam-
ples (dark blue) and seropositive samples (light blue) stratified by the geographic residence of 
sample donors.  D. Distribution of plasma samples by clinical departments of the hospital (dark 875 
blue: totals; light blue: posterior probability > 0.5). E. Individual time courses for repeat samples 
of patients annotated to be SARS-CoV-2 PCR-positive. Shown is the reactivity against the S pro-
tein, for time frames of up to 100 days. Colors represent individual patients. 
 
Fig. 4. Characterization of prepandemic samples. A. Posterior probability were calculated as-880 
suming a Gaussian distribution and visualized for individual antigens (S, RBD and NC) for pre-
pandemic samples vs. copandemic USZ samples drawn in May and June 2020. Prepandemic 
samples exhibited a low posterior probability as they typically reacted against single antigens, 
leading to low rankings in a composite metric. For further testing, comparative samples were 
chosen from the prepandemic era and from May and June 2020. Arrows point to samples of 885 
individuals used in (B), (C), (D). P1-6: prepandemic 1-6; C1-2: COVID1-2. B. Western Blot anal-
ysis of two samples from May/June 2020 (“COVID 1” and “COVID 2”) and several prepandemic 
samples (denoted with 2, 4 and 5). Anti-his-tag antibody was included as a positive control. Lane 
1 = non-transfected Expi293F cell lysate; Lane 2 = Expi293F cell lysates expressing his-tagged 
S, NC and RBD proteins. Black arrows: S; blue arrows: NC; purple arrow: RBD. C. ELISA assays 890 
on the same samples as in B, using SARS-CoV-2 S, NC, RBD and NSP1 as well as control 
proteins (BSA, CMV pp65). D. Soluble recombinant S or RBD were spiked into plasma at 0.04-
88 nM (S) and 0.7-1350 nM (RBD), in the same samples as in B and C, and ELISA was then 
performed with immobilized RBD or S. Data points represent averages of duplicates. Soluble 
antigens suppressed the ELISA signal in the COVID samples but not in the prepandemic sample, 895 
showing that the antibodies present in the latter had lower affinities for SARS-CoV-2 targets. 
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Fig. 5. Assay validation in solution and clonality of anti-S immune response. A. ELISA as-
says of healthy blood donors vs. convalescent individuals. B. Microfluidic-based assessment of 
binding between an Alexa 647-labelled RBD antigen and antibodies in solution. No change in 900 
diffusion coefficient or the associated hydrodynamic radius was observed in control samples, 
while all ELISA-positive samples from convalescent and healthy donors indicated a clear binding 
of antibodies to RBD, confirming the ELISA-based results. C. Western Blot analysis of the same 
individuals tested in (A). Lane 1 = non-transfected Expi293F cell lysate; Lane 2 = Expi293F cell 
lysates expressing his-tagged S, NC and RBD proteins. Black arrows: S. Blue arrows: NC. 905 
D. Competitive ELISA using RBD or S for soluble competition with antibodies in plasma from the 
same individuals as in (A) and (C). Each point is the average of duplicates with error bars except 
for “donor 4” in the competitive ELISA using soluble RBD and immobilization for RBD which is a 
unicate.  
  910 
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Fig. S1. Detailed assay procedure. A. Sample acquisition. B. Experimental workflow using high-
throughput screening platform.  
 
Fig. S2. Comparison of TRABI to a lateral-flow assay developed by Bloom diagnostics.  915 
 
Fig. S3. Prevalence estimation in two large cohorts. A. and B. Half-violin plots showing the 
distribution of anti-S/RBD/NC reactivity in the –log(EC50) scale for the USZ (A) and the BDS (B) 
cohort. Color bar: posterior probability C. and D. Depicted are all the –log(EC50) values calculated 
for S and the RBD for the USZ (C) and the BDS (D) cohort. Posterior probability were calculated 920 
using LDA. E. and. F. Q-Q plots to check the Gaussian distributional assumption of the LDA 
model. For USZ (E) and the BDS (F) cohort respectively, we collapsed the 3 measures per sample 
according to the linear discriminant classifier. We then scaled known positives and negatives to 
mean zero and unit variance and compared their distributions to the univariate Gaussian distribu-
tion via Q-Q plot. We saw that for the relevant upper tail, the distribution of known negatives 925 
followed the normal distribution with only a mild deviation, such that, for instance, the upper one 
percent quantile is reached at 2.04 (E) and 2.00 (F) rather than at their theoretical value of 2.32. 
G. and. H. ROC curves for the USZ (G) and BDS (H) cohorts using the prepandemic samples 
(including the ones from December 2019 and January 2020 for BDS) as condition negatives and 
selected condition positives from both cohorts. I. Using the posterior probabilities from the LDA, 930 
the prevalence of SARS-CoV-2 seropositivity was calculated in prepandemic samples and then 
from December 2019 to July 2020.  
 
Fig. S4. Epidemiological modelling. Modelled number of hospitalized (A) and ventilated (B) 
patients and deaths (C) during the SARS-CoV-2 epidemic in the Canton of Zurich, Switzerland. 935 
The solid lines show the maximum likelihood estimate of the model and the shaded areas corre-
spond to the 95% prediction intervals. The model was fitted to the data indicated as white circles 
and the BDS seroprevalence estimates as shown in Fig. 2D.  
 
Fig. S5. Assay reproducibility using 210 high scoring samples and 122 random samples 940 
(based on results from the high-throughput screen) for binding against S, the RBD, and 
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the NC. A. S binding shows that reproducibility increases at higher values, consistent with in-
creased posterior probabilities. B. Same observation as (A) for the RBD. C. Same observation as 
(A) for the NC. 
 945 
Fig. S6. Characterization of prepandemic and copandemic samples. A. Western Blot analy-
sis. For a better visualization, brightness and contrast have been modified and the images have 
been partially cropped. Original images are shown in Fig. S6. B. Additional ELISA. C. Competitive 
ELISA. 
 950 
Fig. S7. Competitive ELISA probing for NC signal for healthy blood donors and convales-
cent individuals. 
 
Fig. S8. Uncropped and unmodified camera-acquired images of the Western Blots dis-
played in Figs. 4 and 5 and Fig. S6. 955 
 
Table S1. Descriptive statistics of age and sex for all cohorts. Data shown here show basic 
annotations for the USZ as well as for the BDS cohort. Samples from the BDS cohort were fully 
anonymized until March. Demographic and clinical annotations are only available since April 2020 
for bioethical reasons. 960 
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